Protocolsβ€ΊCartilage & Osteoarthritis Support Protocol
IntermediateJoint Regeneration12 weeks

Cartilage & Osteoarthritis Support Protocol

Slow cartilage degradation, reduce osteoarthritic inflammation and stiffness, and support chondrocyte function in early-to-moderate joint degeneration

Patient profile: Adults with grade I–III knee, hip or hand osteoarthritis, chronic chondral wear, or persistent degenerative joint pain seeking a non-surgical regenerative approach

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol β†’
⚠️

This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.

Protocol Stack

BPC-157

Primary

Dose

500 mcg

Frequency

1–2x/day SC

Timing

Morning and evening; SC near the affected joint

Duration

12 weeks

TB-500 (Thymosin Beta-4)

Primary

Dose

5 mg

Frequency

2x/week SC (weeks 1–6), then 1x/week (weeks 7–12)

Timing

Separate from BPC-157 by at least 2 hours

Duration

12 weeks

GHK-Cu

Supporting

Dose

2 mg SC

Frequency

1x/day SC

Timing

Evening

Duration

12 weeks

MK-677

Optional

Dose

10–15 mg

Frequency

1x/day oral

Timing

Before bed

Duration

12 weeks (cycle off and reassess after)

Monitoring Parameters

  • βœ“WOMAC or KOOS questionnaire (pain, stiffness, function) β€” baseline, week 6, week 12
  • βœ“Pain score (NRS 0–10) at rest and on weight-bearing β€” weekly
  • βœ“Range of motion and crepitus assessment β€” biweekly
  • βœ“Fasting glucose / HbA1c if using MK-677 (GH secretagogues raise glucose)
  • βœ“Optional imaging (ultrasound or MRI cartilage mapping) at baseline and week 12 if available

Expected Outcomes

1

Weeks 1–3: Reduced inflammatory pain and stiffness, easier daily movement

2

Weeks 4–8: Improved weight-bearing tolerance and function scores (WOMAC/KOOS)

3

Weeks 9–12: Stabilised pain relief; goal is slowed degeneration and improved function, not guaranteed cartilage regrowth

Contraindications

  • βœ—Active malignancy (trophic and pro-angiogenic peptides)
  • βœ—Poorly controlled diabetes or prediabetes if MK-677 is used β€” drop MK-677 or monitor glucose closely
  • βœ—Active joint infection or recent intra-articular corticosteroid injection (wait β‰₯4 weeks)
  • βœ—Bone-on-bone end-stage (grade IV) osteoarthritis β€” manage expectations; this is supportive, not a substitute for arthroplasty
  • βœ—Known hypersensitivity to peptide components

Clinical Notes

This protocol extends the BPC-157 + TB-500 foundation with chondro-supportive agents for degenerative rather than acute injury. GHK-Cu is dosed systemically here to stimulate collagen and proteoglycan synthesis throughout the joint matrix. MK-677 (ibutamoren) is an oral growth-hormone secretagogue that raises IGF-1, which supports chondrocyte proliferation and collagen turnover β€” it is marked optional because it raises fasting glucose and causes water retention/appetite increase, so it is omitted in anyone with glucose dysregulation. Honest framing matters: human evidence for true cartilage regrowth from peptides is limited; the realistic and well-supported goals are reduced inflammation, slowed degradation, and improved function. Pair with load management, quadriceps/hip strengthening, weight optimisation, and oral collagen + vitamin C. If MK-677 is used, consider a 12-weeks-on / 4-weeks-off cycle and recheck HbA1c.

Case Study

Clinical Practice Example

Male, 58, grade II–III medial knee osteoarthritis, NRS 6/10 on stairs, WOMAC pain 12/20. Wanted to delay knee replacement. Started BPC-157 500 mcg 2x/day SC + TB-500 5 mg 2x/week + GHK-Cu 2 mg/day, MK-677 omitted (borderline HbA1c 5.9%). Added quadriceps strengthening and lost 4 kg. Week 6: NRS 3/10 on stairs, WOMAC pain 7/20. Week 12: NRS 2/10, WOMAC pain 5/20, able to hike 8 km. Decision to defer surgery and repeat a maintenance cycle in 6 months. No adverse events.

← Back to all protocols